Weisheng Pharmaceutical

VISEN Pharmaceuticals (02561.HK) is an innovative biopharmaceutical company focusing on the endocrine field, licensed by Ascendis Pharma to introduce the TransCon technology platform. The company has independently developed a proprietary Dual-Chamber Device (DCD) platform, which separates lyophilized drugs and diluents into two chambers in the same cassette bottle, and bypasses and reconstitutes them in a pen syringe before use, that is, a typical 'dual-chamber cartridge' system, which is used for solubilized biological agents such as lonapegsomatropin. The company has cooperated with WuXi Biologics to promote the localization technology transfer of DCD preparations, and reached a strategic technical cooperation with Tofflon for dual-cavity lyophilized preparations: In August 2026, the dual-cavity lyophilized preparation production line equipment supplied by Tofflon completed factory acceptance (fat) and was delivered to the Chengdu factory, marking the start of the construction of localized commercial production capacity of 'lyophilization in dual-chamber cartridge'. This capability is oriented towards the reconstitution and administration of high-end biological agents, which can significantly improve patient compliance and drug safety, and is expected to become the first dual-cavity lyophilization technology in China.